Safety and Efficacy of the CarboFix Pedicle Screw System

Last updated: April 16, 2019
Sponsor: CarboFix Orthopedics Ltd.
Overall Status: Completed

Phase

N/A

Condition

Ankylosing Spondylitis

Carcinoma

Spinal Stenosis

Treatment

N/A

Clinical Study ID

NCT02039232
CARBOFIX P CLD PPS1
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the safety and efficacy of CarboFix' Pedicle Screw System in the lumbar spine.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is 18 years old or older.

  2. Confirmation that the physical examination of radiopathy, myelopathy or combination isin correlation with the affected level.

  3. Lumbar CT, MRI, or myelography confirms the level of involvement is consistent withthe subject's examination.

  4. Informed consent given by the subject.

Exclusion

Exclusion Criteria:

  1. Subject is not eligible for fixation with market-available fixation means.

  2. Familial history NF2.

  3. Acute traumatic spinal injury with or without neurological signs.

  4. Metabolic bone disease.

  5. History of Paget's disease or other osteodystrophies whether acquired or congenital,including renal osteodystrophy, hyperthyroidism, hypothyroidism hyperparathyroidism,Ehrlers-Danlos-syndrome, osteogenesis imperfecta, achondroplasia, tuberculosis.

  6. History of mental disorder or current psychiatric treatment.

  7. Pregnancy and/or female subjects intending to become pregnant within the expected timeframe of the study and/or female subjects of child bearing age who do not useconventional contraceptive methods.

  8. Immune deficiency disease.

  9. Infection in the location of the operative site, discitis, osteomyelitis, fever and/orleukocytosis (as diagnosed based on the results of CBC and ESR tests).

  10. Scoliosis.

  11. Treatment with drugs that may interfere with bone metabolism such as:

  12. Cumulative dose of 150 mg. of Prednisone or equivalent within the last 6 months.

  13. Calcitonin within the past 6 months.

  14. Bisphosphonates for 30 days or more within the last 12 months.

  15. Bone therapeutic doses of fluoride for 30 days or more within the last 12 months.

  16. Bone therapeutic doses of vitamin D or Vitamin D metabolites for 30 days or morewithin the last 6 months.

  17. Treatment by chemotherapy within the last 12 months.

  18. Lack of willingness to make a commitment to return for required follow up visits.

  19. Drug and/or alcohol abuse.

  20. Morbid obesity.

  21. Metal allergies.

  22. Recent use of other investigational drugs or devices (within the past 30 days).

Study Design

Total Participants: 46
Study Start date:
January 01, 2014
Estimated Completion Date:
February 28, 2018

Connect with a study center

  • Hillel Yafe MC;

    Hadera;,
    Israel

    Site Not Available

  • Hillel Yafe MC; Herzeliya MC

    Hadera; Herzeliya,
    Israel

    Site Not Available

  • Herzliya Medical Center

    Herzliya,
    Israel

    Site Not Available

  • Rizzoli Orthopaedics Institute

    Bolonga,
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.